论文部分内容阅读
OBJECTIVE To explore the biodistribution and anti-tumoractivity of ~(131)I labeled rituximab injected intratumorally orintraperitoneally in vivo in nude mice bearing Raji human Burkitt’s lymphoma xenografts.METHODS The rituximab and the mouse IgG were labeled withNa~(131)I using the IODO-GEN method.BALB/C nude mice werexenografted with ~(131)I-Rituximab or ~(131)I-IgG and killed on the 1st,3rd,7th,and 15th day after injection.The tumor/non-tumor ratio(T/NT)and the dose injected in each gram of the tissue(%ID/g)from12 organs or tissues of interest,e.g.tumor,blood,were calculated.The long and short axes of each tumor were measured by calipersat 2-3-day intervals after treatment,and the growth inhibition ofthe tumor was calculated using the MIRD formula.RESULTS When comparing intraperitoneal injection(IP)andintratumoral injection(IT)of ~(131)I-IgG,intratumoral injection of~(131)I-rituximab produced a significantly higher tumor/non-tumorratio in all tissues and organs of interest on the 1st,3rd,and 7thday,respectively(P<0.05).The %ID/g of tumor was 1.4-1.7-foldand 1.5-3.7-fold in the IP and IgG IT groups,respectively,but the%ID/g of non-tumors was significantly lower in the IP group andIgG IT group.Similarly,the tumor growth was greatly inhibitedby intratumoral injection of the ~(131)I-rituximab,whereas it wasless inhibited by other forms of the treatment(P<0.05).However~(131)I-rituximab injected intratumorally inhibited tumor growth ina dose-dependent manner.The inhibition rate was less with alow dose(75μCi)and greater with a high dose(150μCi),yet thedifference was not significant(P>0.05).CONCLUSION Tumors can absorb the highest amount of theradiolabelled antibodies,and the tumor/non-tumor ratios in thegroup with intratumoral injection of the ~(131)I-rituximab resulted inthe optimal anti-tumor activity.
OBJECTIVE To explore the biodistribution and anti-tumoractivity of ~ (131) I labeled rituximab injected intratumorally or intraperitoneally in vivo in nude mice bearing Raji human Burkitt’s lymphoma xenografts. METHODS The rituximab and the mouse IgG were labeled with Na ~ (131) I using the IODO -GEN method. BALB / C nude mice were xenografted with 131 I-Rituximab or 131 I-IgG and killed on the 1st, 3rd, 7th, and 15th day after injection. The tumor / non-tumor ratio T / NT) and the dose injected in each gram of the tissue (% ID / g) from 12 organs or tissues of interest, eg tumor, blood, were calculated. The long and short axes of each tumor were measured by calipersat 2-3 -day intervals after treatment, and the growth inhibition of the tumor was calculated using the MIRD formula. INVRESULTS When comparing intraperitoneal injection (IP) and intratumoral injection (IT) of ~ (131) I- IgG, intratumoral injection of ~ rituximab produced a significant higher tumor / non-tumorratio in all tissues and organs of interest on the 1s The% ID / g of tumor was 1.4-1.7-fold and 1.5-3.7-fold in the IP and IgG IT groups, respectively, but the% ID / g of non -tumors was significantly lower in the IP group and IgG IT group.Similarly, the tumor growth was greatly inhibited by intratumoral injection of ~ (131) I-rituximab, it itless inhibited by other forms of the treatment (P <0.05) .However (131) I-rituximab injected intratumorally inhibited tumor growth in a dose-dependent manner. The inhibition rate was less with alow dose (75 μCi) and greater with a high dose (150 μCi), yet the difference was not significant (P> 0.05). CONCLUSION Tumors can absorb the highest amount of the radiolabelled antibodies, and the tumor / non-tumor ratios in the group with intratumoral injection of 131 I-rituximab resulted in optimal anti-tumor activity.